Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a
combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab),
in comparison with a standard steroid + tacrolimus double drug regimen